This article was originally published in Start Up
In 1997, reconstructive surgeon Peter Johnson, MD, the founder and president of the Pittsburgh Tissue Engineering Initiative, saw an opportunity in TissueInformatics Inc. to support the tissue engineering industry with informatics tools that enabled the analysis and digital cataloguing of tissue images and data. But it appears that the usefulness of TissueInformatics' platform extends beyond tissue engineering--the company has come along at just the right time to also serve a growing need for digital tissue analysis tools by biorepositories as well as by pharmaceutical companies using tissue samples to validate genomics discovery efforts.
You may also be interested in...
Despite the in silico research ideals of many genomicists, no one has yet found a way around the basic requirement for using human tissue in gene expression studies-a broad array of it, well characterized, from healthy and diseased patients, and from world populations at large. That's why start-ups, drug discovery firms and others are creating a new resource: biorepositories--banks of tissue samples and data to serve the diagnostic, pharmaceutical and tissue engineering industries. As providers of services and products to research-based companies, these companies believe they are operating in a market that ranges from $500 million to $5 billion.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.